Compare AIN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | EWTX |
|---|---|---|
| Founded | 1895 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.5B |
| IPO Year | 1987 | 2021 |
| Metric | AIN | EWTX |
|---|---|---|
| Price | $50.31 | $21.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $64.25 | $35.89 |
| AVG Volume (30 Days) | 427.4K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,148,512,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $41.15 | $10.60 |
| 52 Week High | $83.65 | $33.38 |
| Indicator | AIN | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 43.20 |
| Support Level | $49.70 | $22.77 |
| Resistance Level | $53.88 | $25.00 |
| Average True Range (ATR) | 1.53 | 1.44 |
| MACD | 0.45 | -0.51 |
| Stochastic Oscillator | 49.73 | 16.89 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.